Merrimack Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MACK Nasdaq 8731 http://www.merrimackpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Merrimack Pharmaceuticals Inc

Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting - Apr 9th, 2018 5:30 am
Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications - Apr 4th, 2018 6:15 am
Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non-Small Cell Lung Cancer - Mar 14th, 2018 5:30 am
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 - Mar 13th, 2018 7:45 am
Edited Transcript of MACK earnings conference call or presentation 12-Mar-18 12:30pm GMT - Mar 12th, 2018 5:06 pm
Merrimack Pharmaceuticals, Inc. to Host Earnings Call - Mar 12th, 2018 5:30 am
Merrimack Provides Business Update and Reports 2017 Financial Results - Mar 12th, 2018 4:27 am
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer - Mar 12th, 2018 4:25 am
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference - Mar 5th, 2018 5:00 am
Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)? - Feb 27th, 2018 3:11 am
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer - Feb 26th, 2018 4:55 am
What's in the Cards for Merrimack (MACK) in Q4 Earnings? - Feb 23rd, 2018 7:10 am
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - Feb 20th, 2018 5:00 am
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference - Feb 15th, 2018 5:00 am
New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018 - Feb 6th, 2018 6:25 am
Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference - Jan 4th, 2018 6:00 am
Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound? - Dec 11th, 2017 2:12 am
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors - Nov 30th, 2017 4:50 am
With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job? - Nov 20th, 2017 6:04 pm
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team - Nov 14th, 2017 5:00 am